跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CABENUVA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
CABENUVA
Authorized
STANDARD
CABENUVA
viiv healthcare ulc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
5b2ffc01c559b538
Company
viiv healthcare ulc
Type
Standard
Approval Details
Approval Id
5b2ffc01c559b538
Drug Approval Canada Name
CABENUVA
Product Name
CABENUVA
Status
Marketed
Status Date
2020-09-21
Original Market Date
2020-09-21
Din
02497220
Drug Class
Human
Dosage Form
Kit , Suspension (Extended-Release)
Route Of Administration
Intramuscular
Schedule
Prescription
Ahfs
08:18.08.12
Atc Original
J05AR ANTIVIRALS FOR TREATMENT OF HIV INFECTIONS, COMBINATIONS
Atc Name
j 05 ar
Aig Number
0262115001
Company Name
viiv healthcare ulc
Company Address
1400, 75 Rue Queen, Montreal, Quebec, Canada, H3C 2N6
Active Ingredients
RILPIVIRINE
300 MG / ML
CABOTEGRAVIR
200 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
5b2ffc01c559b538
Type
Standard
Back to Health Canada Approvals